ArticleJournal of clinical microbiology2020
COVID-19 Serology at Population Scale: SARS-CoV-2-Specific Antibody Responses in Saliva.
Article in Journal of clinical microbiology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 167 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
167 citing papers in PubMed, 3 syntheses or guidelines pooled it, 259 citations in OpenAlex.
- Antibody tests for identification of current and past infection with SARS-CoV-2.The Cochrane database of systematic reviews · 2022Pooled it
- Saliva is suitable for SARS-CoV-2 antibodies detection after vaccination: A rapid systematic review.Frontiers in immunology · 2022Pooled it
- Evaluation of saliva as a complementary technique to the diagnosis of COVID-19: a systematic review.Medicina oral, patologia oral y cirugia bucal · 2021Pooled it
- mRNA COVID-19 vaccination induces minimal IgA in saliva in the absence of prior clinical or subclinical infection.Vaccine · 2026Article
- Rural targeted messaging, multiplex salivary measurement, and rural equity in SARS-CoV-2 antibody testing: Protocol overview of a SeroNet investigation.Contemporary clinical trials communications · 2026Article
- Salivary IgG Antibody Response to SARS-CoV-2 as a Non-Invasive Assessment of Immune Response-Differences Between Vaccinated Children and Adults.Biomedicines · 2026Article
- Roles of children, isolation measures and socioeconomic status in SARS-CoV-2 household transmission: a retrospective cohort study in a southern US city.BMJ public health · 2026Article
- Development of an enteric pathogen multiplex immunoassay to measure antibody responses in blood and saliva for integrated serology applications.Journal of immunological methods · 2025Article
- Culturally targeted messaging and racial equity in SARS-CoV-2 antibody testing by multiplex salivary measurement: Protocol overview of a SeroNet investigation.Brain, behavior, & immunity - health · 2025Article
- Article
- Early, Robust Mucosal Secretory Immunoglobulin A but not Immunoglobulin G Response to Severe Acute Respiratory Syndrome Coronavirus 2 Spike in Oral Fluid Is Associated With Faster Viral Clearance and Coronavirus Disease 2019 Symptom Resolution.The Journal of infectious diseases · 2025Article
- Piloting an external quality assurance program (QAP) for COVID-19 antigen rapid diagnostic tests (Ag-RDTs): findings and lessons learned from Cambodia.BMJ open quality · 2025Article
- The omicron variant of SARS-CoV-2 drove broadly increased seroprevalence in a public university setting.PLOS global public health · 2025Article
- Severe Acute Respiratory Syndrome Coronavirus 2 Antibody Prevalence and Associated Risk Factors in a Large Cohort of US Children.Open forum infectious diseases · 2025Article
- Performance and feasibility of self-microsampling of capillary blood and saliva for serological testing of SARS-CoV-2.PloS one · 2025Article
- Salivary Immunoglobulin a Alterations in Health and Disease: A Bibliometric Analysis of Diagnostic Trends from 2009 to 2024.Antibodies (Basel, Switzerland) · 2024Article
- Application of machine learning algorithms to identify serological predictors of COVID-19 severity and outcomes.Communications medicine · 2024Article
- Inter-laboratory harmonization of microsphere immunoassays for SARS-CoV-2 antibody detection in dried blood spots and oral fluids.bioRxiv : the preprint server for biology · 2024Article
- SARS-CoV-2 antibody prevalence by industry, workplace characteristics, and workplace infection prevention and control measures, North Carolina, USA, 2021 to 2022.Annals of work exposures and health · 2024Article
- Severe acute respiratory syndrome coronavirus 2-reactive salivary antibody detection in South Carolina emergency healthcare workers, September 2019-March 2020.Epidemiology and infection · 2024Article
107 more citing papers are in PubMed but not listed here.
Corrections and comments
- Update of
Authors and funding
21 authors at 4 institutions in 1 country.
Funding
Abstract
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the cause of an ongoing pandemic that has infected over 36 million and killed over 1 million people. Informed implementation of government public health policies depends on accurate data on SARS-CoV-2 immunity at a population scale. We hypothesized that detection of SARS-CoV-2 salivary antibodies could serve as a noninvasive alternative to serological testing for monitoring of SARS-CoV-2 infection and seropositivity at a population scale. We developed a multiplex SARS-CoV-2 antibody immunoassay based on Luminex technology that comprised 12 CoV antigens, mostly derived from SARS-CoV-2 nucleocapsid (N) and spike (S). Saliva and sera collected from confirmed coronavirus disease 2019 (COVID-19) cases and from the pre-COVID-19 era were tested for IgG, IgA, and IgM to the antigen panel. Matched saliva and serum IgG responses (
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.